Key result
An IFN-gamma-expressing recombinant coxsackievirus vector completely protects animals against subsequent lethal CVB3 infections by activating the immune system in a strong and long-lasting manner.
Why the study?
Does an IFN-gamma-expressing recombinant coxsackievirus vector prevent CVB3-induced myocarditis in animal models?
Population
Animal models susceptible to Coxsackievirus B3 (CVB3)-induced myocarditis
Design
Review
Authors
Loading...
Supports preclinical IFN-gamma vector vaccines for CVB3; leaves open human translation and efficacy.
Does an IFN-gamma-expressing recombinant coxsackievirus vector prevent CVB3-induced myocarditis in animal models?
Recombinant coxsackievirus vectors expressing IFN-gamma represent a promising preclinical vaccine strategy for preventing CVB3-induced myocarditis.
Henke et al. (2008) conducted a review in CVB3-induced myocarditis. IFN-gamma-expressing recombinant coxsackievirus vector was evaluated on Protection against subsequent lethal infections. An IFN-gamma-expressing recombinant coxsackievirus vector completely protects animals against subsequent lethal CVB3 infections by activating the immune system in a strong and long-lasting manner.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: